These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36069950)

  • 1. Effect of add-on alpha lipoic acid on psychopathology in patients with treatment-resistant schizophrenia: a pilot randomized double-blind placebo-controlled trial.
    Mishra A; Reeta KH; Sarangi SC; Maiti R; Sood M
    Psychopharmacology (Berl); 2022 Nov; 239(11):3525-3535. PubMed ID: 36069950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alpha-lipoic acid alone and combined with clozapine reverses schizophrenia-like symptoms induced by ketamine in mice: Participation of antioxidant, nitrergic and neurotrophic mechanisms.
    Vasconcelos GS; Ximenes NC; de Sousa CN; Oliveira Tde Q; Lima LL; de Lucena DF; Gama CS; Macêdo D; Vasconcelos SM
    Schizophr Res; 2015 Jul; 165(2-3):163-70. PubMed ID: 25937462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. α-Lipoic Acid as Adjunctive Treatment for Schizophrenia: An Open-Label Trial.
    Sanders LLO; de Souza Menezes CE; Chaves Filho AJM; de Almeida Viana G; Fechine FV; Rodrigues de Queiroz MG; Gonçalvez da Cruz Fonseca S; Mendes Vasconcelos SM; Amaral de Moraes ME; Gama CS; Seybolt S; de Moura Campos E; Macêdo D; Freitas de Lucena D
    J Clin Psychopharmacol; 2017 Dec; 37(6):697-701. PubMed ID: 29053478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. α-Lipoic Acid as Adjunctive Treatment for Schizophrenia: A Randomized Double-Blind Study.
    De Lima DN; Costa Filho CWL; Frota IJ; de Oliveira ALB; Menezes CES; Chaves Filho AJM; Viana GA; Campos EM; Collares M; de Queiroz MGR; da Cruz Fonseca SG; Vasconcelos SMM; Macêdo DS; Sanders LLO
    J Clin Psychopharmacol; 2023 Jan-Feb 01; 43(1):39-45. PubMed ID: 36584248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor.
    Lane HY; Lin CH; Green MF; Hellemann G; Huang CC; Chen PW; Tun R; Chang YC; Tsai GE
    JAMA Psychiatry; 2013 Dec; 70(12):1267-75. PubMed ID: 24089054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
    Lane HY; Chang YC; Liu YC; Chiu CC; Tsai GE
    Arch Gen Psychiatry; 2005 Nov; 62(11):1196-204. PubMed ID: 16275807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, controlled trial of omega-3 fatty acids plus an antioxidant for relapse prevention after antipsychotic discontinuation in first-episode schizophrenia.
    Emsley R; Chiliza B; Asmal L; du Plessis S; Phahladira L; van Niekerk E; van Rensburg SJ; Harvey BH
    Schizophr Res; 2014 Sep; 158(1-3):230-5. PubMed ID: 24996507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjunctive α-lipoic acid reduces weight gain compared with placebo at 12 weeks in schizophrenic patients treated with atypical antipsychotics: a double-blind randomized placebo-controlled study.
    Kim NW; Song YM; Kim E; Cho HS; Cheon KA; Kim SJ; Park JY
    Int Clin Psychopharmacol; 2016 Sep; 31(5):265-74. PubMed ID: 27276401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study.
    Modabbernia A; Rezaei F; Salehi B; Jafarinia M; Ashrafi M; Tabrizi M; Hosseini SM; Tajdini M; Ghaleiha A; Akhondzadeh S
    CNS Drugs; 2013 Jan; 27(1):57-65. PubMed ID: 23233269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia.
    Farokhnia M; Sabzabadi M; Pourmahmoud H; Khodaie-Ardakani MR; Hosseini SM; Yekehtaz H; Tabrizi M; Rezaei F; Salehi B; Akhondzadeh S
    Psychopharmacology (Berl); 2014 Feb; 231(3):533-42. PubMed ID: 24013610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.
    de Lucena D; Fernandes BS; Berk M; Dodd S; Medeiros DW; Pedrini M; Kunz M; Gomes FA; Giglio LF; Lobato MI; Belmonte-de-Abreu PS; Gama CS
    J Clin Psychiatry; 2009 Oct; 70(10):1416-23. PubMed ID: 19906345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia.
    Weiser M; Heresco-Levy U; Davidson M; Javitt DC; Werbeloff N; Gershon AA; Abramovich Y; Amital D; Doron A; Konas S; Levkovitz Y; Liba D; Teitelbaum A; Mashiach M; Zimmerman Y
    J Clin Psychiatry; 2012 Jun; 73(6):e728-34. PubMed ID: 22795211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized clinical trial of histamine 2 receptor antagonism in treatment-resistant schizophrenia.
    Meskanen K; Ekelund H; Laitinen J; Neuvonen PJ; Haukka J; Panula P; Ekelund J
    J Clin Psychopharmacol; 2013 Aug; 33(4):472-8. PubMed ID: 23764683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, Added to Clozapine for the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Lin CH; Lin CH; Chang YC; Huang YJ; Chen PW; Yang HT; Lane HY
    Biol Psychiatry; 2018 Sep; 84(6):422-432. PubMed ID: 29397899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial.
    Akhondzadeh S; Safarcherati A; Amini H
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):253-9. PubMed ID: 15694232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness.
    Barnes TR; Leeson VC; Paton C; Marston L; Davies L; Whittaker W; Osborn D; Kumar R; Keown P; Zafar R; Iqbal K; Singh V; Fridrich P; Fitzgerald Z; Bagalkote H; Haddad PM; Husni M; Amos T
    Health Technol Assess; 2017 Sep; 21(49):1-56. PubMed ID: 28869006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanocurcumin as an Add-on to Antipsychotic Drugs for Treatment of Negative Symptoms in Patients With Chronic Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Study.
    Hosseininasab M; Zarghami M; Mazhari S; Salehifar E; Moosazadeh M; Fariborzifar A; Babaeirad S; Hendouei N
    J Clin Psychopharmacol; 2021 Jan/Feb 01; 41(1):25-30. PubMed ID: 33347019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. L-carnosine as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial.
    Ghajar A; Khoaie-Ardakani MR; Shahmoradi Z; Alavi AR; Afarideh M; Shalbafan MR; Ghazizadeh-Hashemi M; Akhondzadeh S
    Psychiatry Res; 2018 Apr; 262():94-101. PubMed ID: 29427913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Citicoline (CDP-choline) add-on therapy to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial.
    Ghajar A; Gholamian F; Tabatabei-Motlagh M; Afarideh M; Rezaei F; Ghazizadeh-Hashemi M; Akhondzadeh S
    Hum Psychopharmacol; 2018 Jul; 33(4):e2662. PubMed ID: 29901250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Raloxifene adjunctive therapy for postmenopausal women suffering from chronic schizophrenia: a randomized double-blind and placebo controlled trial.
    Kianimehr G; Fatehi F; Hashempoor S; Khodaei-Ardakani MR; Rezaei F; Nazari A; Kashani L; Akhondzadeh S
    Daru; 2014 Jul; 22(1):55. PubMed ID: 25012765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.